Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
| ▸ | MMP12 | P39900 | 6/20 | 0.56 |
| ▸ | MMP13 | P45452 | 6/20 | 0.56 |
| ▸ | MMP14 | P50281 | 6/20 | 0.56 |
| ▸ | MMP9 | P14780 | 5/20 | 0.56 |
| ▸ | MMP8 | P22894 | 5/20 | 0.56 |
| ▸ | MMP16 | P51512 | 5/20 | 0.56 |
| ▸ | MMP1 | P03956 | 4/20 | 0.56 |
| ▸ | MMP3 | P08254 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434908 | 0.87 | CYP2D6 (0.56) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL22652932 | 0.85 | CYP2D6 (0.60) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL10777232 | 0.85 | CYP2D6 (0.49) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL3394732 | 0.85 | CYP2D6 (0.83) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL3162315 | 0.84 | CYP2D6 (0.48) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL8761231 | 0.83 | HTR6 (0.55) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL5672590 | 0.82 | MMP2 (0.50) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL10181290 | 0.82 | HSD11B1 (0.59) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL1465909 | 0.80 | CYP2D6 (0.51) | CYP2D6MMP2MMP12MMP13MMP14 | |
| SCHEMBL4613268 | 0.80 | HTR6 (0.57) | MMP2MMP12MMP13MMP14MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2925408-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| CN-104822420-A | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN LA ROCHE | 2015-08-05 | — | — | CN | disclosed |
| WO-2014086667-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| CN-102216249-A | Naphthylacetic acids | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2242745-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | FABP4, GPR119, PGC | CYP2D6 177/4885MMP2 3523/4885MMP12 2126/4885 |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | CYP2D6 316/4885MMP2 2689/4885MMP12 3416/4885 |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | SCD, CPT1A, SCD5 | CYP2D6 546/4885MMP2 2696/4885MMP12 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.